-
Artificial Intelligence Approach for the Discovery of Autoantigen Recognition By B-Cell Lymphomas2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology vaccines and immunoinformatics approaches
David Medina, Julieta Sepúlveda-Yáñez, Diego Álvarez-Saravia, Roberto Uribe-Paredes, Hendrik Veelken, Marcelo A. Navarrete
3citations -
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Joanna Ewa Drozd-Sokolowska, Luuk A. Gras, Laurien G.A. Baaij, Linda Köster, Emma Nicholson, Peter Dreger, +20 more
3citations -
Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
Josu de la Fuente, Jacques‐Emmanuel Galimard, Arnaud Dalissier, Mohsen Al Zahrani, Ali Debsan Alahmari, Fahad I. Almohareb, +14 more
3citations -
Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Marie José Kersten, Kirsten Saevels, Évelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, +9 more
3citations -
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Marie José Kersten, Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Maria Theresa Kuipers, Évelyne Willems, Sébastien Anguille, +14 more
3citations -
Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-
Martin Bornhaeuser, Christoph Schliemann, Johannes Schetelig, Christoph Röllig, Michael Krämer, Bertram Glaß, +21 more
2citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments
Jeanette Walter, Kim Kricheldorf, Yannic Schumacher, Susanne Isfort, Jörg Chromik, Beatrice Drexler, +4 more
2citations -
A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, Jean‐Jacques Kiladjian, +14 more
2citations -
Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML - the SAL/AMLCG Vincent Trial
Leo Ruhnke, Christoph Schliemann, Lars R. Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, +26 more
2citations -
Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, J Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
2citations -
MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kirsi Marjaana Manz, Tina M. Schnoeder, Francesca Palandri, Filippo Branzanti, Heike Luise Pahl, Martin Grießhammer, +20 more
2citations